Transgenic mouse models that specifically targetted the ATF6 branch in cardiomyocytes have shown that activation of ATF6 decreased myocardial damage after ischemia and/or reperfusion, while disruption of endogenous ATF6 increased pro-apoptotic signaling and aggravated cardiac function [46,52]. The gene discussed is ATF6; the disease is ischemia.